Dato’ Dr. Norhizan bin Ismail

Dato’ Dr. Norhizan bin Ismail

Independent Non-Executive Director

Dato’ Dr. Norhizan Bin Ismail (“Dato’ Dr. Norhizan”) was appointed as the Independent Non-Executive Director of Pecca Group Berhad on 17 September 2021. He was also appointed as a member of Audit and Risk Management Committee, Nomination Committee and Remuneration Committee.

He obtained a Medical Doctor (MD) Degree from Universiti Sains Malaysia (USM) in August 1986. He is also a Master Degree in Public Health (MPH) from University of Malaya in 1996. In view of his experience and contributions in the field of Public Health, he was gazetted as a Public Health Physician in 2002. He subsequently obtained certification through a two years Epidemic Intelligent Program (EIP) training in Ministry of Health (MOH) Malaysia from 2004 to 2006. He was then further acknowledged by MOH Malaysia and Academy of Medicine of Malaysia as a Public Health Specialist in 2011 and was listed in the National Specialist Register (NSR) of Malaysia. The Council of Malaysian Public Health Physicians’ Association has also acknowledged his motivation and vast contributions to Public Health thus admitting him as a Fellow of Public Health Medicine Malaysia on 16 July 2018.

Dato’ Dr. Norhizan is very passionate in his field of expertise and has dedicated his heart and soul for nearly 35 years with MOH Malaysia. Throughout his tenure, he has served all levels of healthcare services which includehospitals,DistrictHealthofficesand State Health Departments where he took on strategic post as Pahang and Kedah State Health Director and was conferred Datukship from both states. His career further flourished when he served as the Director of Medical Development Division MOH Malaysia. His highest achievement was the appointment as Deputy Director General of Health (Medical) MOH Malaysia prior to his official retirement on 17 August 2021. He does not hold any directorship in other public companies or listed issuers.

Dato’ Dr. Norhizan does not have any family relationship with any Director and/or major shareholder of the Company.

He has attended all the six (6) Board Meetings held during the financial year ended 30 June 2023.

Back to Leadership